Prelude CTO, Alicia Browner, will Join Dynamic Panel of Data Tech Experts to Speak at the 2019 SCDM Annual Conference

The 2019 SCDM Annual Conference, the World’s No. 1 Clinical Data Management Event, will be held September 29 – October 2 in Baltimore, Maryland. Every year, business and industry leaders gather to discuss advances in DM and new technologies that are driving clinical trials and regulatory standards of best practice.

SCDM is focused on improving data strategies that promote innovation, while maintaining data integrity. Sharing in these enthusiasms, Prelude Dynamics is proud to partner up to exhibit and speak at this year’s premier data management event.

Alicia Browner, Ph.D., Prelude’s Chief Technology Officer, will join an astute panel of experts that will discuss artificial intelligence in clinical trials and how it is empowering organizations to take their data to the next level.  Attendees will learn how AI is the key to cleaner data and faster outcomes – introducing them to techniques that will save time while managing large data sets.

Panel Session Details:

  • Session 23 – “Getting Out of the Weeds – Using AI and Strategic Data Analysis Approaches to Monitor Studies” with Alicia Browner  |  Tuesday, October 01, 2019: 1:30 PM – 3:00 PM

 [Note: Make sure to check the SCDM program schedule for any updates in speaking sessions and times]

Prelude Dynamics is honored to be given the opportunity to contribute to meaningful conversations on compliance and data quality as more clinical trials are integrating with EDC platforms.

Stop by booth, #602, to get a first-hand sneak-peek of Prelude’s most exciting software upgrade yet, VISION 10.0™! There will be team members on-hand to provide demos and answer any related questions.

For more information about SCDM and to register, please visit https://www.scdm.org/scdm-2019-annual-conference/

See you in Baltimore!!

Prelude Dynamics Releases Latest VISION Software Upgrade

Prelude Dynamics Releases New Software Version: VISION 10.0 – Exceptional User Experience and Industry-Driven Enhancements 

Prelude Dynamics, LLC, has recently announced the release of its latest software upgrade, VISION 10.0. The new version includes many new features in Composer, VISION’s do-it-yourself study builder, including enhanced usability, additional form logic and bulk editing capabilities for a more efficient study build experience. Monitors will enjoy the new risk-based-monitoring tools and streamlined report creation. As the #1 Electronic Data Capture (EDC) software in animal health, Prelude Dynamics offers a premium EDC solution for both human and animal clinical trials at affordable pricing. VISION 10.0 simplifies data monitoring practices, streamlines study cycles and accelerates approved submissions to the FDA and the Center of Veterinary Medicine (CVM). As quoted from Richard Tieken, the President of Prelude Dynamics,

Prelude has been advancing the conduct of clinical trials internationally with automation for 15 years. VISION 10.0 continues the excellence and has included significant improvements to fulfill the needs of our Full-service and DIY clients.  We know what Data Managers find useful, because we also do that job!  Our clients see results that ease building, managing, and submitting clinical data to FDA/CVM and EMA, and our clients should see even more successful submissions with VISION 10.0.

With this release, users can expect significant functionality enhancements to data capture, data analytics, and data exportation within an improved and friendlier user interface that is also more optimized for mobile-device and offline data capture. Some note-worthy enhancements include:

  • Form libraries to save and re-use forms from past studies
  • Automated invoicing functionality by site
  • A new two-way lab interface with Marshfield Labs that enables automatic submission directly to the lab without manual intervention from the sites
  • Improved AE and ConMed dictionary coding capabilities
  • Enhanced export capabilities including CDISC export format and greater data format configurations
  • A built-in risk-based monitoring tool that highlights the most critical fields in the study as it progresses (AI driven)

Tommy Jackson, COO at Prelude Dynamics, is excited for the release,

Efficiency and compliance are top of mind to every sponsor and CRO with whom we’ve interacted. The enhancements to VISION Composer were specifically designed to address these demands. We are excited for clinicians and data managers to be introduced to an affordable EDC alternative with the same or greater level of functionality and compliance than they are used to.

Focusing on a seamless user experience, Composer offers a fresh new look and reboot to its graphical user interface (GUI), now enabling form building and study schedule assembly all in one central place. Building, copying, and organizing study forms is now easier than ever with a form library that collects previously-built forms and stores them for use in future, per-client Composer studies. Site invoicing, a feature previously only available in the full-service version of VISION, is now configurable within the tool and a new standout feature that tracks site payments and study milestones within the DIY tool. This is just one of the multiple customizable features and functions to be expected in this year’s product release. Prelude Dynamics is focused on the future of animal and human health clinical trial advancement, leveraging industry-driven software updates to its EDC platform and enabling clients to build and configure faster, more complex study protocols in one encompassing product platform with greater data accuracy.

Dr. Alicia Browner participates in Artificial Intelligence Panel at SQA CVIC Meeting

Alicia Browner, Ph.D., Chief Technology Officer at Prelude Dynamics, presented today at the Society of Quality Assurance CVIC Meeting. Dr. Browner was selected to present as one of the panelist on the topic of artificial intelligence (AI) in health care and clinical trials.

The presentation focused on approaches to validation and how the FDA treats artificial intelligence technologies. The ultimate goal of AI is to get the computer to think and act like humans with the focus on thinking and acting rationally in order to be able to perform some of the functions we currently rely on humans to do. Currently, popular AI include Alexa, Siri and Sophia, all of which can do the simple task of looking for and retrieving information and sometime taking action such as playing a song. Yet, AI could do so much more.

Dr. Browner worked with neural networks and optimization in aerospace before founding Prelude Dynamics. She is currently developing an AI risk-based monitoring (RBM) tool to aid clinical study monitors in managing and monitoring the data. VISION™ Clinical Trial Optimization Platform already contains an innovative technology in its dictionary coding function. The function instantaneously matches the best options as the user types, allowing them to quickly select from a dictionary like WHO Drug, that contains over 300,000 entries. This IntelliMatch functionality is also used in search, reports, and exports as well as in the combo fields. Prelude is also planning to augment this technology with a learning algorithm to help offer the most prevalent options.

Dr. Browner said, “AI is going to change the landscape of clinical research. At Prelude we are strategically implementing our AI strategy and helping lead the industry into its implementation.”

Applications in artificial intelligence use methodologies to present knowledge, plan, process natural language, perceive things like speech, facial and object recognition, move (motion, as in robotics), and have social intelligence. One of the challenges, as an example, is that communication is known to be 80% or more non-verbal. So how do you teach a computer to understand that? The current strategy is machine learning.

Machine learning is the process of teaching a computer to learn by providing it with information and learning experiences. Initially, programmers teach the computer to learn through supervised learning. The end goal is for the computer to learn unsupervised. In order to accomplish this, technologies such as Baysian Networks, Neural Networks and Evolutionary Algorithms can be applied to assist decision making.